Humira Biosimilars Prepare For US Competition In 2023
Landmark LOE Opportunity Looms, With Multiple Adalimumab Launches Expected
The advent of biosimilar competition to Humira in the US in 2023 represents the largest loss-of-exclusivity opportunity ever for the off-patent industry. But with a host of biosimilar sponsors awaiting launches throughout the year, it remains to be seen how competition will play out.
